RBC Capital raises Chemed stock price target on strong results By Investing.com

Chemed reported Q1 2026 EPS of $5.65, beating the $5.34 estimate, while revenue came in at $657.5 million versus $651.02 million expected. RBC Capital raised its price target to $436 from $422 and kept a Sector Perform rating after the company lifted guidance, citing strong VITAS census growth and margin performance. Shares jumped more than 10% Friday and were up 9.16% for the week, though Roto-Rooter margins remain pressured.

Analysis

CHE is starting to look less like a clean “earnings beat” story and more like a self-funding quality compounder with a near-term operating cushion. The important second-order effect is that hospice census momentum plus Medicare cap headroom reduce the probability of an ugly earnings reset over the next few quarters, which tends to compress short interest and forces slow-money holders to chase on each raise. That makes the stock more resilient than a standard post-earnings pop because the upgrade cycle can continue even if the multiple does not expand much further.

The more interesting debate is that the market is still underweighting the asymmetry between VITAS and Roto-Rooter. VITAS is effectively a defensive growth engine with regulatory protection, while Roto-Rooter is a margin drag whose pressure can be masked until labor or lead-gen costs reaccelerate. If management can keep the hospice mix doing the heavy lifting, CHE can support dividend growth and modest multiple support even in a choppier tape; if not, the “quality” narrative can crack quickly because investors are paying for consistency, not cyclical operating leverage.

The consensus likely misses how much of the upside is already about durability rather than upside surprise. A higher target after a 10% move can still be constructive, but the risk/reward gets less compelling if the market has already repriced the guided path; the next leg needs either another census inflection or evidence that Roto-Rooter margins have stabilized. Conversely, any sign of cap headroom eroding or hospice growth normalizing would likely hit the stock harder than the current valuation suggests because the thesis is built on a narrowing set of “safe” earnings drivers.

Key Decisions for Investors

• Stay long CHE on 1-3 month horizon, but use pullbacks after overbought moves to add; upside is now more about multiple durability than fresh estimate expansion, while downside is limited unless hospice trends roll over.
• Buy CHE call spreads 2-4 months out to express a controlled continuation trade; the setup favors modest further re-rating, but capped upside argues for defined risk rather than outright stock.
• If already long, hedge with a partial short in a more labor-sensitive home-services peer or broader small-cap healthcare basket; the key relative risk is that Roto-Rooter margin pressure reasserts itself and drags the story back to mixed fundamentals.
• Monitor quarterly VITAS census and Medicare cap cushion closely; if those metrics remain constructive for the next two prints, add on strength because the probability of a downward guidance reset falls materially.
• Take profits on any move that pushes CHE well above revised fair value without a second positive catalyst; the market is likely to reward execution, but not indefinitely pay for a single-source quality story.